TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17502629

Group type: EXPERIMENTAL
Intervention: Depression care manager working with primary care physicians to provide algorithm-based care
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Usual care practices
Number of subjects: 1226
Study: 15916064

Group type: EXPERIMENTAL
Intervention: Ergonomics Intervention Program (EIP)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Non-EIP group
Number of subjects: 172
Study: 11994554

Group type: EXPERIMENTAL
Intervention: Patients with APSTD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients without APSTD
Number of subjects: 0
Study: 11721378

Group type: EXPERIMENTAL
Intervention: Leunase 6,000 KU/m2, continuous intravenous injection every day for 8 times
Number of subjects: 20

Group type: COMPARATOR
Intervention: Leunase 6,000 KU/m2, continuous intravenous injection every other day for 8 times
Number of subjects: 20
Study: 7585846

Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg as a 1-hour i.v. infusion every 24 hours)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 500 mg every 3 hours (six times daily) for 3 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1,000 mg TID for 3 days
Number of subjects: 18
Study: 1702340

Group type: EXPERIMENTAL
Intervention: Curbicin (from pumpkin seeds and dwarf palm plants)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 158142

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 34

Group type: COMPARATOR
Intervention: Suggestion
Number of subjects: 34
Study: 30896062

Group type: EXPERIMENTAL
Intervention: Endocuff Vision-assisted colonoscopy (EVAC)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 360
Study: 28750935

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir 400 mg plus rilpivirine 600 mg (4-week group)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir 600 mg plus rilpivirine 900 mg (8-week group)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Oral cabotegravir plus abacavir-lamivudine (oral treatment group)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Injection-site reactions (all groups)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Serious adverse events (intramuscular groups)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Serious adverse events (oral treatment group)
Number of subjects: 309
Study: 25700386

Group type: EXPERIMENTAL
Intervention: Antenatal multiple micronutrient supplementation
Number of subjects: 841

Group type: COMPARATOR
Intervention: Iron and folic acid supplements (Control)
Number of subjects: 841
Study: 23727969

Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss program
Number of subjects: 0
Study: 22112328

Group type: EXPERIMENTAL
Intervention: Systematic fetal movement counting from pregnancy week 28
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Standard antenatal care (routine fetal movement counting discouraged)
Number of subjects: 1123
Study: 19184686

Group type: EXPERIMENTAL
Intervention: Mock prescriptions
Number of subjects: 144

Group type: COMPARATOR
Intervention: Reading a description of the regimen
Number of subjects: 144
Study: 17678657

Group type: EXPERIMENTAL
Intervention: Implantable 2-channel peroneal nerve stimulator
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional walking device (ankle-foot orthosis, orthopedic shoes, or no device)
Number of subjects: 29
Study: 15140331

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 0
Study: 11956353

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 3 kcal min(‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion at 1 kcal min(‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 8
Study: 9589821

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 0.1% cream pretreatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Testosterone transdermal delivery (TTD) without pretreatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Inactive occlusive dressing (control)
Number of subjects: 82
Study: 8028511

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.03 mg.kg ideal body weight‐1.d‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2662431

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 alpha‐OH‐D3) 1.0 microgram/day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 alpha‐OH‐D3) 2.0 micrograms/day
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 alpha‐OH‐D3)
Number of subjects: 140
Study: 241366

Group type: EXPERIMENTAL
Intervention: i.v. diazepam (0.3 mg/kg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: i.v. flunitrazepam (0.03 mg/kg) combined with pethidine (1 mg/kg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: i.v. droperidol (5 mg) combined with fentanyl (0.2 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: i.v. diazepam (0.3 mg/kg) combined with pethidine (1 mg/kg)
Number of subjects: 62
Study: 30810968

Group type: EXPERIMENTAL
Intervention: Laser tattoo removal
Number of subjects: 89

Group type: COMPARATOR
Intervention: Wait-list (control group)
Number of subjects: 89
Study: 30933244

Group type: EXPERIMENTAL
Intervention: In vitro fertilization (IVF)
Number of subjects: 275686

Group type: COMPARATOR
Intervention: Non-IVF (control)
Number of subjects: 275686
Study: 27768119

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 25844610

Group type: EXPERIMENTAL
Intervention: Own Make-up
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control Make-up
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: No Make-up
Number of subjects: 27
Study: 22775982

Group type: EXPERIMENTAL
Intervention: Head Mounted Display (HMD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three Screen Display (TSD)
Number of subjects: 0
Study: 20947493

Group type: EXPERIMENTAL
Intervention: distributed constraint‐induced therapy (dCIT)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: bilateral arm training (BAT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: control treatment (CT)
Number of subjects: 66
Study: 19934630

Group type: EXPERIMENTAL
Intervention: Usual medical care and community weight-management/fitness resources plus a brief intervention highlighting benefits of activity independent of weight-management
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual medical care and community weight-management/fitness resources
Number of subjects: 26
Study: 17309447

Group type: EXPERIMENTAL
Intervention: Intralipid infusion for 2 hours
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control infusion (Glycerol)
Number of subjects: 9
Study: 15517669

Group type: EXPERIMENTAL
Intervention: Modified sling placed at the mid-urethra without tension
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional suburethral sling
Number of subjects: 48
Study: 11677469

Group type: EXPERIMENTAL
Intervention: Thermal tumor ablation (TTA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Expandable metal stent insertion
Number of subjects: 65
Study: 9825553

Group type: EXPERIMENTAL
Intervention: Bionator
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Twin Block
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Bass
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control
Number of subjects: 47
Study: 8572855

Group type: EXPERIMENTAL
Intervention: Eccentric left ventricular hypertrophy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Normal left ventricular anatomy
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Concentric left ventricular remodeling
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Concentric left ventricular hypertrophy
Number of subjects: 94
Study: 2569194

Group type: EXPERIMENTAL
Intervention: 300 mg dextropropoxyphene napsylat (DP) daily for 16 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 64951

Group type: EXPERIMENTAL
Intervention: Bleomycin (intramuscular injection)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Bleomycin (intravenous injection)
Number of subjects: 88
Study: 30721655

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard antihypertensive treatment
Number of subjects: 9361
Study: 28353144

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg daily for 2 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Megestrol acetate (40 mg for 2 weeks per month for 2 months)
Number of subjects: 50
Study: 25560319

Group type: EXPERIMENTAL
Intervention: Health IT tool intervention (n = 1,143)
Number of subjects: 3655

Group type: EXPERIMENTAL
Intervention: Health IT tool intervention (n = 486 with elevated LDL)
Number of subjects: 3655

Group type: COMPARATOR
Intervention: Control group (n = 703)
Number of subjects: 3655

Group type: EXPERIMENTAL
Intervention: Follow-up safety monitoring
Number of subjects: 3655
Study: 23738545

Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (1 individual session and 11 group sessions)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Individual support
Number of subjects: 405
Study: 21075038

Group type: EXPERIMENTAL
Intervention: Pilates mat exercises
Number of subjects: 34

Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 34
Study: 19711195

Group type: EXPERIMENTAL
Intervention: Sensitive search filter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Precise search filter
Number of subjects: 0
Study: 16912489

Group type: EXPERIMENTAL
Intervention: Almodin‐Moron trocar
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tulipan‐Bruner trocar
Number of subjects: 6
Study: 15292036

Group type: EXPERIMENTAL
Intervention: Tube feeding (NG or PEG feeding)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Oral feeding (control group)
Number of subjects: 38
Study: 15353388

Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg/day
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Risperidone 2 mg/day
Number of subjects: 537

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Risperidone 0.5 mg/day
Number of subjects: 537
Study: 10872994

Group type: EXPERIMENTAL
Intervention: Composite material
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer Photac-Fil
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Tetric
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Erosion/non-carious cervical cavities
Number of subjects: 197
Study: 9174136

Group type: EXPERIMENTAL
Intervention: Trinucleotide repeat polymorphism (GCT)n within the MICA gene
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) combined with fluorescent‐based automated fragment detection technology
Number of subjects: 604
Study: 8261811

Group type: EXPERIMENTAL
Intervention: Topical glycolic acid lotion
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 3949246

Group type: EXPERIMENTAL
Intervention: Intra-abdominal instillation of bupivacaine 2 mg/kg bw
Number of subjects: 0
Study: 3052266

Group type: EXPERIMENTAL
Intervention: Bromocriptine (up to 30 mg per day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 7
Study: 31154887

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour language therapy (CBLT) programme delivered in 24 group sessions over 12 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 92
Study: 28780372

Group type: EXPERIMENTAL
Intervention: Cimaglermin alfa (0.8mg/kg and 2.6mg/kg) in mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimaglermin alfa in diabetic mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimaglermin alfa in human heart failure patients
Number of subjects: 0
Study: 25472825

Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) (n=61)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PI-based ART (n=59)
Number of subjects: 120
Study: 23433852

Group type: EXPERIMENTAL
Intervention: Once-daily DRV/r
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Twice-daily DRV/r
Number of subjects: 429
Study: 20840345

Group type: EXPERIMENTAL
Intervention: Licochalcone A (LA) lotion, applied twice daily for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydrocortisone (HC) lotion, applied twice daily for 6 weeks
Number of subjects: 30
Study: 19447940

Group type: EXPERIMENTAL
Intervention: Land-based therapeutic exercise
Number of subjects: 3800

Group type: COMPARATOR
Intervention: Land-based therapeutic exercise (fewer than 12 direct supervision occasions)
Number of subjects: 3800
Study: 17301824

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combined (losartan 50 mg/daily + ramipril 5 mg/daily)
Number of subjects: 57
Study: 15014270

Group type: EXPERIMENTAL
Intervention: Behavioral-graded activity
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care (physical therapy)
Number of subjects: 105
Study: 11160464

Group type: EXPERIMENTAL
Intervention: Physiotherapy at home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiotherapy as an outpatient
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 0
Study: 9932142

Group type: EXPERIMENTAL
Intervention: GLA + EPA
Number of subjects: 65

Group type: COMPARATOR
Intervention: Coconut oil placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: GLA + EPA (after switching from placebo)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: GLA + EPA (continued treatment)
Number of subjects: 65
Study: 8050541

Group type: EXPERIMENTAL
Intervention: Almitrine (8 micrograms.kg‐1.min‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3056506

Group type: EXPERIMENTAL
Intervention: Metronidazole treatment (2 g single doses on days 1 and 3) for male partners
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo treatment for male partners
Number of subjects: 107
Study: 31901403

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Screening positive for depression
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Gender (male)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Advanced disease
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Preference for place of death
Number of subjects: 300
Study: 30659070

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus and Bifidobacterium animalis subspecies lactis)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 411
Study: 28669288

Group type: EXPERIMENTAL
Intervention: MOMCare collaborative care depression intervention (choice of brief interpersonal psychotherapy or pharmacotherapy or both)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Enhanced maternity support services (MSS-Plus)
Number of subjects: 164
Study: 25666215

Group type: EXPERIMENTAL
Intervention: Panel Management support (with PMAs)
Number of subjects: 8153

Group type: EXPERIMENTAL
Intervention: Panel Management support plus education
Number of subjects: 8153

Group type: COMPARATOR
Intervention: Control group (no panel management support)
Number of subjects: 8153
Study: 22878873

Group type: EXPERIMENTAL
Intervention: Sequential HRP scoring protocol (automatic and then manual for residual cases)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Manual HRP scoring
Number of subjects: 366

Group type: COMPARATOR
Intervention: Automatic HRP scoring
Number of subjects: 366

Group type: COMPARATOR
Intervention: Subsequent manual HRP scoring
Number of subjects: 366
Study: 21311168

Group type: EXPERIMENTAL
Intervention: Eccentric ergometer sessions (EET)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Conventional strength training (RET)
Number of subjects: 28
Study: 19338158

Group type: EXPERIMENTAL
Intervention: Salvia injection (SI) plus composite amino acid (CAA) for 7 days
Number of subjects: 106

Group type: COMPARATOR
Intervention: Composite amino acid (CAA) alone for 7 days
Number of subjects: 106
Study: 16412750

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study: 15255164

Group type: EXPERIMENTAL
Intervention: irinotecan/cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: irinotecan in combination with gemcitabine, taxanes, and other new agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: irinotecan combined with a platinum agent
Number of subjects: 0
Study: 12587182

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (2.5%) infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isotonic saline (0.9%) infusion
Number of subjects: 17
Study: 9577356

Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide 250 micrograms twice daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 58
Study: 8169175

Group type: EXPERIMENTAL
Intervention: Sexually abused children
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-sexually abused children
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 3285637

Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplementation (400 IU, 5-7 times weekly)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 30355512

Group type: EXPERIMENTAL
Intervention: Daily TPTD for 24 months (Rx-Naïve)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cyclic TPTD for 48 months (Rx-Naïve)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Daily TPTD for 24 months (ALN-Rx)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cyclic TPTD for 48 months (ALN-Rx)
Number of subjects: 89
Study: 28980452

Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide (initial dose 80 mg/day, can be doubled if poor response)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent infusion of furosemide (twice-daily bolus injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High diuretic dose (furosemide >120 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low diuretic dose (furosemide ≤120 mg/day)
Number of subjects: 0
Study: 24978046

Group type: EXPERIMENTAL
Intervention: Narrative blogs
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Compliant blog comments
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Defiant blog comments
Number of subjects: 181

Group type: COMPARATOR
Intervention: Non-narrative blogs
Number of subjects: 181
Study: 23883138

Group type: EXPERIMENTAL
Intervention: Good School Toolkit plus implementation support
Number of subjects: 2520

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 2520
Study: 21062921

Group type: EXPERIMENTAL
Intervention: Filtered 100 kVp images
Number of subjects: 1152

Group type: COMPARATOR
Intervention: 100 kVp with a filter
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: 80 kVp and 100 kVp images with nonlinear noise filter
Number of subjects: 1152
Study: 19847131

Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy combined with an intensive rehabilitation program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intensive rehabilitation program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 21
Study: 18229570

Group type: EXPERIMENTAL
Intervention: St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Beck Anxiety Inventory (BAI)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory, 2nd edition (BDI)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 58
Study: 15499762

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11905959

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (600 mg alpha‐tocopherol, 1000 mg ascorbic acid, 32 mg beta‐carotene)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 13
Study: 9337497

Group type: COMPARATOR
Intervention: Standard group counseling (STND)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Individualized relapse prevention (RP)
Number of subjects: 98
Study: 7944656

Group type: EXPERIMENTAL
Intervention: Adjuvant total parenteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No adjuvant total parenteral nutrition (Control)
Number of subjects: 0
Study: 2904825

Group type: EXPERIMENTAL
Intervention: Bisoprolol (10‐20 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atenolol (50‐100 mg)
Number of subjects: 14
Study: 29164399

Group type: EXPERIMENTAL
Intervention: Ultra-high molecular weight hyaluronic acid (UHMW-HA, Fermathron S)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Medium molecular weight hyaluronan (MMW-HA, Hyalubrix 60)
Number of subjects: 54

Group type: COMPARATOR
Intervention: MMW-HA (subgroup analysis)
Number of subjects: 54
Study: 27575791

Group type: EXPERIMENTAL
Intervention: Telephone-delivered intervention
Number of subjects: 178

Group type: COMPARATOR
Intervention: Face-to-face delivered intervention
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Early therapeutic alliance
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Treatment retention
Number of subjects: 178
Study: 24692284

Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 301

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 301
Study: 22687601

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus lapatinib
Number of subjects: 579

Group type: COMPARATOR
Intervention: Paclitaxel plus placebo
Number of subjects: 579
Study: 20727091

Group type: EXPERIMENTAL
Intervention: 3 days of specific training
Number of subjects: 51